Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral ...
Cocrystal Pharma (COCP) announces the approval from the Institutional Review Board, IRB, at Emory University School of Medicine to initiate a Phase 1b human challenge study with CDI-988. This study ...
BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the approval from the Institutional Review Board (IRB) at Emory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback